Genome Engineering Market to be dominated by CRISPR Technique through 2027
Growing applications of genomics in different application
areas such as human genetic disorders, agriculture, drug discovery, etc. is expected to drive the growth of global genome
engineering market through 2027
According to TechSci Research report, “Genome
Engineering Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2017-2027”,
the global genome engineering market
is anticipated to grow at a significant rate in the forecast period, 2023-2027.
The growing prevalence of different chronic diseases especially cancer and
different genetic disorders and need to get efficient treatment for them is
expected to drive the growth of global genomic engineering market. Additionally,
the sudden outbreak and spread of pandemic COVID-19 has significantly increased
the importance and role of genomic engineering. For instance, gene editing
approaches such as CRISPR-Cas12/13-based SHERLOCK, DETECTR, antisense peptide
nucleic acids, ribozymes, aptamers, among others have proved to be vital in
such pandemic outbreaks. These techniques help in shorter and easier diagnosis
to more targeted virus detection and killing.
However,
the high cost of instrumentations and equipment used in genomic engineering
technique can pose threat to the overall market growth on account of
affordability constraints associated with small & medium sized
pharmaceutical companies and academic & research institutions. Also, lack
of awareness and adoption especially in developing nations can further restrict
the market growth. Besides, lack of skilled professionals to perform the
genomic engineering technique and use the instrumentations can further slowdown
the market growth.
Browse over XX market data Figures
spread through 110
Pages and an in-depth TOC on "GENOME ENGINEERING MARKET"
The
global genome engineering market is segmented into by technology, by delivery
method, application, by end user and by region.
Based on technology, the market can be categorized into
CRISPR, TALEN, ZFN, Antisense and others. The CRISPR segment is expected to dominate the market in the
coming years on account of various technical advantages associated with this
technique such as targeted gene disruption, guide RNA-specific recovery, and
regulation. These benefits have accelerated the adoption of CRISPR/Cas9
technology in a relatively broad range of applications. CRISPR clinical
applications have found widespread applications. This is evidenced by the
growing number of ongoing clinical trials using gene-editing techniques to
treat a variety of diseases such as cancer, AIDS, and genetic diseases. Apart
from human health, this technology is increasingly being used in agriculture
and animal breeding.
Among the different end users, the segment of pharmaceutical &
biotechnology companies held the biggest market share for genome engineering. This
can be ascribed to the increased focus of these company’s research &
development activities to develop different treatments and drugs. Additionally,
to create cutting-edge technology, multinational biotechnology & pharmaceutical
companies are collaborating with small companies and startups. For instance, in
April 2021, CANbridge Pharmaceuticals, Inc. and LogicBio Therapeutics, Inc.,
signed a strategic collaboration and licensing agreement to address rare and
serious diseases. CANbridge Pharmaceuticals, Inc. obtained rights to the latter
company's gene-editing platforms as a result of this agreement.
Based on delivery method, the market can be split into ex-vivo
and in-vivo. The ex-vivo segment dominated the market in 2021 on account of
various advantages that come with this mode type, namely the simplicity of
controlling DNA modification. Ex-vivo delivery has grown due to
the increased use of this delivery strategy and the expanding clinical
trial pipeline that uses genome editing tools.
Major operating companies operating in
global genome engineering market are:
- Merck KGaA
- Sangamo Therapeutics, Inc.
- Genscript Biotech Corp
- CRISPR Therapeutics AG
- Editas Medicine, Inc.
- Precision BioSciences, Inc.
- Horizon Discovery Group plc
- Lonza Group Ltd.
- OriGene Technologies, Inc.
- Transposagen Biopharmaceuticals, Inc
Various companies operating in the market are following strategies such
as mergers & acquisitions, collaborations, new therapy development,
increasing research & development activities, launching clinical trials and
filing patent applications in order to stay competitive and have an edge over
the other players operating in the market. For instance, in May 2019, Thermo
Fisher Scientific acquired Brammer Bio to increase its global presence in the
market with the addition of the expertise of Brammer Bio in the manufacturing
of vectors for genes and cell therapies.
DOWNLOAD FREE SAMPLE REPORT
Customers can also request
for 10% free customization on this report.
“The North America region is expected to dominate the
global genome engineering market during the forecast period. This can be
attributed to increasing research & development expenditure and funding
related to genomic research in the region especially in United States and Canada.
Additionally, early adoption and advancements related to the technique in the
region are supporting the market growth” said Mr. Karan Chechi, Research
Director with TechSci Research, a research based global management consulting
firm.
“Genome
Engineering Market - Global Industry Size, Share, Trends, Opportunity, and
Forecast, 2017-2027 Segmented By Technology (CRISPR,
TALEN, ZFN, Antisense, Others), By
Delivery Method (Ex-Vivo v/s In-Vivo), By
Application ( Cell Line Engineering, Genetic Engineering,
Diagnostic Applications, Drug Discovery & Development, Others),
By End User ( Pharmaceutical &
Biotechnology Companies, Academic & Research Institutions, Others)
and By Region”, has evaluated the future growth potential of global genome engineering market
and provides statistics & information on market size, structure, and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global genome engineering market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com